Overview

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Status:
Withdrawn

Trial end date:
2025-08-20

Target enrollment:

Participant gender:

Summary

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Linrodostat
Nivolumab